Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors

Published:2015-03-27 Issue:3 Volume:33 Page:641-651
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Nakamichi Shinji,Nokihara Hiroshi,Yamamoto Noboru,Yamada Yasuhide,Fujiwara Yutaka,Tamura Yosuke,Wakui Hiroshi,Honda Kazunori,Mizugaki Hidenori,Kitazono Satoru,Tanabe Yuko,Asahina Hajime,Yamazaki Naoya,Suzuki Shigenobu,Matsuoka Mieko,Ogita Yoshitaka,Tamura Tomohide

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-015-0229-3.pdf

Reference32 articles.

1. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179–185

2. Fang JY, Richardson BC (2005) The MAPK signaling pathways and colorectal cancer. Lancet Oncol 6:322–327

3. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257–262

4. Fecher LA, Amaravadi RK, Flaherty KT (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20:183–189

5. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813–822

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

2. Natural products with 1,2-oxazine scaffold: occurrence, chemical diversity, bioactivity, synthesis, and biosynthesis;Natural Product Reports;2023

3. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy;Cellular Oncology;2022-09-23

4. Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3–4 NSCLC patients;BMC Medical Genomics;2022-02-22

5. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma;Journal of Immunotherapy and Precision Oncology;2022-02-01